• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs

    2018-12-07 06:21:40YuchenBaiXiaoxiaChenLikunHouJunQianTaoJiangCaicunZhouMaciejCiebiadaDepartmentofGeneralandOncologicalPulmonologyUniversityClinicalHospitalNorbertBarlickiMedicalUniversityofLodzLodzPolandDepartmentofUrologyShanghaiGeneralH
    Cancer Biology & Medicine 2018年4期

    Yuchen Bai, Xiaoxia Chen, Likun Hou, Jun Qian, Tao Jiang, Caicun Zhou, Maciej CiebiadaDepartment of General and Oncological Pulmonology, University Clinical Hospital Norbert Barlicki, Medical University of Lodz, Lodz 0, Poland; Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 000, China; Department of Medical Oncology; Department of Pathology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 00, China; Department of Medical Oncology, Suzhou Cancer Center, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou 1000, China

    ABSTRACT Objective: Epidermal growth factor receptor (EGFR) activation was reported to upregulate programmed death-ligand 1 (PD-L1)expression in lung cancer cells and subsequently contribute to immune escape, indicating its critical role in EGFR-driven lung tumors. This study characterized PD-L1 expression in patients with surgically resected EGFR-mutant non-small cell lung cancer(NSCLC). The effect of PD-L1 expression on clinical outcomes was also investigated in advanced EGFR-mutant NSCLC treated with EGFR-tyrosine kinase inhibitors (TKIs).Methods: In total, 73 patients with surgically resected NSCLC and EGFR mutations were identified. PD-L1 expression and CD8+tumor-infiltrating lymphocyte (TIL) density were assessed by immunohistochemistry. A literature review of publications that assessed the predictive and prognostic value of PD-L1 expression in advanced EGFR-mutant NSCLC patients treated with EGFRTKIs was performed.Results: Nineteen (26.0%) patients were positive for PD-L1 expression, which was significantly associated with concomitant KRAS mutation (P = 0.020) and marginally associated with higher CD8+ TILs density (P = 0.056). Positive PD-L1 expression was associated with markedly inferior overall survival (OS) in multivariate analysis (P = 0.032). The combination of PD-L1 and CD8+TILs expression could be used to stratify the population into three groups with distinct prognoses. A meta-analysis of six publications showed that positive PD-L1 expression was not associated with OS [hazard ratio (HR) = 0.90; 95% confidence interval (CI), 0.42–1.38] or progression-free survival (HR = 1.03; 95 CI, 0.73–1.33) in advanced EGFR-mutant NSCLC patients receiving EGFR-TKIs.Conclusions: PD-L1 expression tended to correlate with CD8+ TIL expression, concomitant KRAS mutation, and poor survival in surgically resected EGFR-mutant NSCLC. PD-L1 expression was neither the predictive nor the prognostic factor in advanced EGFR-mutant NSCLC patients treated with EGFR-TKIs.

    KEYWORDS Non-small cell lung cancer; EGFR mutation; PD-L1; CD8; survival

    Introduction

    Targeted therapy on epidermal growth factor receptor(EGFR)-activating mutations has revolutionized the treatment landscape of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC)1. Several large-scale phase 3 trials have demonstrated the superior efficacy of firstand second-generation EGFR tyrosine kinase inhibitors(TKIs) to standard platinum-based chemotherapy in the first-line setting2-4. However, almost all responders acquired drug resistance after 9–12 months (acquired resistance), and 30% of the initial cohorts showed no response to EGFR-TKIs(primary resistance)1,5-7. A series of resistance mechanisms have been associated with primary and/or acquired resistance, including Bcl-2 family member (BIM) deletion polymorphism, second site mutations, downstream or bypass signaling pathway activation, and histological transformation; however, 25%–30% of acquired resistance and half of primary resistance mechanisms remain undetermined1,7. Therefore, drug resistance is the major challenge for the application of EGFR-TKI in EGFR-mutant NSCLC. There is an urgent need to identify more effective biomarkers to better predict the efficacy of EGFR-TKIs.

    Immune checkpoints are orchestrated by a set of costimulatory and co-inhibitory molecules to regulate the activation and effector functions of tumor-infiltrating lymphocytes (TILs)8. Blockade of inhibitory immune checkpoints by antibodies may release the immune inhibition of effector T cells, especially CD8+ T cells9. To date,therapeutic antibodies targeting programmed cell death 1 (PD-1) and its ligand (PD-L1) have been associated with remarkable response rates in various cancers and are another significant breakthrough in the treatment of patients with advanced NSCLC. Three PD-1/PD-L1 antibodies, including nivolumab, pembrolizumab, and atezolizumab, have been approved for second-line or subsequent treatment of advanced NSCLC for their promising anti-tumor effect compared to that of standard chemotherapy10-13.Furthermore, pembrolizumab was approved in the first-line setting for patients with PD-L1 expression ≥ 50%14,15.However, in clinical practice, Gainor et al.16reported a limited effect of PD-1/PD-L1 inhibitors in patients with EGFR-mutant NSCLC. A recent phase 2 clinical study reported a 12.2% objective response rate (ORR) to an anti-PD-L1 antibody among EGFR-mutant NSCLC patients, with at least 25% of tumor cells expressing PD-L1, compared to an ORR of 3.6% in those with PD-L1 expression < 25%17,suggesting the clinical value of PD-L1 expression in EGFR-mutant NSCLC patients treated with anti-PD-L1 antibody.However, there are limited data to characterize the PD-L1 expression in EGFR-mutant NSCLC patients. A recent preclinical study demonstrated that the expression of mutant EGFR in bronchial epithelial cells could significantly induce PD-L1 expression and that EGFR-TKIs could reduce PD-L1 expression in NSCLC cell lines with activated EGFR18,indicating a potential relationship between PD-L1 expression and EGFR mutations in NSCLC. Several groups, therefore,investigated the predictive and prognostic value of PD-L1 expression on EGFR-mutant NSCLC patients treated with EGFR-TKIs. However, their findings were paradoxical. Lin et al.19reported that PD-L1 expression was associated with a better response to EGFR-TKI and longer survival, while Tang et al.20suggested that PD-L1 expression was neither the predictive nor the prognostic factor in EGFR-mutant NSCLC patients treated with EGFR-TKIs.

    Therefore, the current study aimed to characterize PD-L1 expression in patients with surgically resected EGFR-mutant NSCLC and to investigate the effect of PD-L1 expression on clinical outcomes in patients with advanced EGFR-mutant NSCLC treated with EGFR-TKIs. Because the antitumor effect of anti- PD-1/PD-L1 antibodies is mainly dependent on the proliferation and activation of CD8+ TILs8,9, we further evaluated the prognostic value of the combination of PD-L1 expression and CD8+ TIL density in surgically resected NSCLC with EGFR mutations.

    Patients and methods

    Patient cohort

    We retrospectively identified patients who underwent surgical resection of the lung (lobectomy or pulmonectomy)due to the histologically-confirmed NSCLC, between 2011 and 2015, at Shanghai Pulmonary Hospital and our cooperative medical centers. The major patient baseline characteristics including age, sex, smoking history, histology[World Health Organization (WHO) classification]21, and stage of NSCLC at initial diagnosis were collected. Never smoker was defined as a person who has smoked fewer than 100 cigarettes during their lifetime. This study was conducted in accordance with the provisions of the Declaration of Helsinki and was approved by the ethics committee of Shanghai Pulmonary Hospital. The exclusion criteria included histologically-confirmed SCLC, stage IIIB-IV before surgery, and chemotherapy and/or radiotherapy administered before surgery. Patients who could not provide adequate samples for EGFR detection and PD-L1/CD8 staining or who disagreed with the study protocols were ineligible.

    PD-L1 expression analysis

    PD-L1 expression was evaluated by immunohistochemistry(IHC) as described previously22. In brief, tumor sections of formalin-fixed and paraffin-embedded specimens were treated with 3% H2O2for 10 min, blocked with 5% goat serum, and incubated with a primary anti-human PD-L1 antibody (#13684, clone E1L3N, Cell Signaling Technology,Danvers, MA, diluted 1:200). Next, a peroxidase-labeled secondary antibody (REAL EnVision Detection Reagent Peroxidase Rabbit/Mouse, DAKO, Denmark) was applied to the sections for 30 min at room temperature. PD-L1 positive/negative expression was defined using a cut-off value of 5%23-26.

    CD8+ TIL analysis

    A mouse anti-CD8 monoclonal antibody (M7103, clone C8144B, DAKO, Denmark) was utilized for CD8+ TIL density assessment as described previously27,28. TILs were enumerated on immunostained CD8 preparations and scored using a four-tier scale (details in supplemental file).The cut-off point for high/low CD8+ TIL expression was 5%.

    EGFR and KRAS mutation detection

    EGFR and KRAS mutation analyses were conducted at Shanghai Pulmonary Hospital & Thoracic Cancer Institute,Tongji University School of Medicine (Shanghai, China). The samples were tested using an Amplification Refractory Mutation System (ARMS) as previously described (Amoy Diagnostics Co., Ltd., Xiamen, China)22,29,30.

    Meta-analysis

    We performed a publication search of the PubMed/Medline, EMBASE, Google Scholar, Cochrane Library, and Web of Science databases through December 31, 2017, using“l(fā)ung cancer” and “PD-L1” and “EGFR-TKI” and their related words. Data on the relationship between PD-L1 expression and overall survival (OS), progression-free survival (PFS), and clinicopathological characteristics in EGFR-mutant NSCLC patients treated with EGFR-TKIs were collected from publications meeting the eligibility criteria(Supplementary Table S1). The details of our methodology are described in the supplemental file.

    Statistical analysis

    Categorical variables were analyzed using the Chi-square or Fisher’s exact tests. Continuous variables were analyzed by analysis of variance and Tukey’s multiple comparison tests.Kaplan-Meier curves were used to assess patient survival, and log-rank tests were used to evaluate the significance of differences between two or four groups. Cox proportional hazards models were used for uni- and multivariate survival analyses to calculate the hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). The OS was calculated from the date of lung cancer diagnosis to death from any cause or was censored at the last follow-up date.P-values less than 0.05 (two-sided) were considered to be significant. Meta-analysis was conducted using STATA version 12.0 (Stata Corporation, TX). All statistical analyses were performed using IBM SPSS Statistics for Windows,version 22.0 (IBM Corp., Armonk, NY, USA).

    Results

    Characterization of PD-L1 expression in EGFR-mutant NSCLC

    In total, 201 patients with surgically resected NSCLC were initially enrolled. After EGFR detection, 73 patients with surgically resected EGFR-mutant NSCLC were finally identified. Most (63.0%) were < 65 years old at the time of diagnosis. Forty-two (57.5%) of the patients were female and 44 (60.3%) were never-smokers. The most predominant histological type was adenocarcinoma (71 patients). Three patients (4.1%) had concomitant KRAS mutations. Nineteen patients (26.0%) had positive PD-L1 expression and 22 (30.1%) had high CD8+ TILs density. Representative images of IHC for PD-L1 expression and CD8+ TILs are shown in Supplementary Figure S1. The clinical features of the 73 patients are summarized in Table 1.

    There was a significant correlation between PD-L1 expression and concomitant KRAS mutations (P = 0.020).Patients with high CD8+ TIL density were more likely to have positive PD-L1 expression, but the relationship did not reach statistical significance (P = 0.056). There were no significant differences in PD-L1 expression in terms of age(P = 0.570), gender (P = 0.297), smoking status (P = 0.429),pathologic types (adenocarcinoma vs. non-adenocarcinoma)(P = 0.973), pathologic stages (I/IIIA vs. IIIB/IV) (P = 0.591),and lymph node metastasis (P = 0.661).

    Prognostic value of PD-L1 expression in surgically resected NSCLC with EGFR mutation

    The median follow-up time was 25.7 months (range, 5.6–54.9 months). Univariate analysis revealed that patients with positive PD-L1 expression showed a marginally shorter OS than that in patients with negative expression (HR = 2.339,95% CI: 0.992–9.835; P = 0.057) (Table 2 and Figure 1A).High CD8+ TIL density tended to be associated with longer OS but it did not reach the statistical significance (HR =0.409, 95% CI: 0.185–1.246; P = 0.138) (Table 2 and Figure 1B). Other factors including gender, age, smoking status,lymph node metastasis, and EGFR mutant types were not associated with OS (Table 2). Multivariate analyses suggested that positive PD-L1 expression was significantly associated with a shorter OS (HR = 2.995, 95% CI: 1.097–8.178; P =0.032) (Table 2). While patients with high CD8+ TIL expression showed a longer OS than that in those with low CD8+ TIL expression, the difference was not statisticallysignificant (HR = 0.296, 95% CI: 0.080–1.103; P = 0.070)(Table 2).

    Table 1 Baseline characteristics of the study population

    We further assigned the population into four groups according to PD-L1 and CD8+ TIL expression. The median OS was not reached in the PD-L1+/CD8-high and PD-L1-/CD8-high expression groups but was 29.0 months in the PD-L1+/CD8-low group and 45.0 months in the PD-L1-/CD8-low group (P = 0.056, Figure 1C). Patients with PD-L1-/high CD8+ TIL density expression had the longest OS (HR =0.196, P = 0.072), while the PD-L1+/CD8-low group had the shortest OS (HR = 3.087, P = 0.020) (Supplementary Figure S2).

    Features of the studies included in the metaanalysis

    A total of 192 potentially relevant studies were screened.Most of the excluded publications were reviews, comments,duplications, or studies with incomplete data. The current study assessed 648 cases from six publications19,20,31-34to investigate both the predictive and prognostic value of PD-L1 expression in advanced EGFR-mutant NSCLC patients treated with EGFR-TKIs. The main features of the eligible studies are shown in Table 3 and Supplementary Table S2.In addition, prognostic and predictive data on OS and PFS were obtained from the included studies. Figure 2 depicts a flowchart of publication inclusion.

    Predictive and prognostic value of high PD-L1 expression in EGFR-mutant NSCLC treated with EGFR-TKIs

    A meta-analysis was performed to evaluate the overall effect of positive PD-L1 expression in the studies containing predictive and prognostic data. The pooled results showed that positive PD-L1 expression was not correlated with OS(HR = 0.90, 95% CI: 0.42–1.38; P > 0.05; Figure 3A).Similarly, the pooled results indicated that positive PD-L1 expression was not associated with PFS (HR = 1.03, 95% CI:0.73–1.33; P > 0.05; Figure 3B). Both results showed high heterogeneity (I2= 80.3%, P < 0.001; I2= 60.8%; P = 0.013;respectively).

    Publication bias

    Sensitivity analysis was conducted by deleting one study at one time to assess its effect on the pooled HRs. Deletion of the study by Meniawy et al.31slightly decreased the heterogeneity in the analysis of pooled HRs of PFS and OS.No other studies influenced the pooled results. Begg’s funnel plots and Egger’s tests were used to evaluate the publication bias. The Begg’s funnel plot was symmetric, and Egger’s tests suggested no evidence of publication bias (Supplementary Figure S3).

    Discussion

    Emerging evidence suggested that blocking PD-1/PD-L1 showed a limited efficacy in patients with EGFR-mutant NSCLC. A preclinical study reported that EGFR activation could regulate PD-L1 expression in lung cancer, indicating a sophisticated interaction between EGFR mutations andPD-L1 expression. Improved understanding of PD-L1 expression in EGFR-mutant NSCLC would contribute to the development of more effective immunotherapy. Additionally,clarifying the predictive and prognostic value of PD-L1 expression in EGFR-mutant NSCLC patients treated with EGFR-TKIs would be helpful to precisely determine the populations who could most benefit from EGFR-TKIs therapy. To achieve these goals, the current study systematically investigated the clinicopathological features of PD-L1 expression in surgically resected EGFR-mutant NSCLC and the effect of this expression on clinical outcome patients with advanced EGFR-mutant NSCLC treated with EGFR-TKIs. Our results showed that positive PD-L1 expression was significantly correlated with concomitant KRAS mutations and seemed to be associated with high CD8+ TILs density without statistical significance, mainly due to the small sample size. Positive PD-L1 expression was associated with a significantly shorter OS, and the combination of PD-L1 and CD8+ expression could further stratify the population into three groups with distinct prognoses. Furthermore, a meta-analysis of six publications indicated that positive PD-L1 expression was neither a predictive nor a prognostic factor in advanced EGFR-mutant NSCLC patients treated with EGFR-TKIs.

    Table 2 Univariate and multivariate analyses of clinical parameters on OS in patients with EGFR muttaions.

    Figure 1 Prognostic value of PD-L1 expression (A) CD8 TILs expression (B) and combination of PD-L1 and CD8 TILS expression (C) in surgically resected NSCLC with EGFR mutation.

    Several studies have reported a positive association between EGFR mutations and positive PD-L1 expression in completely resected NSCLC20,35-37. However, few studies have characterized PD-L1 expression in patients with EGFR-mutant NSCLC. In our study, we observed that positive PD-L1 expression was significantly correlated with concomitant KRAS mutations in patients with EGFR-mutant NSCLC. PD-L1 is frequently highly expressed in NSCLC with driver mutations, which subsequently activates key oncogenic pathways such as PI3K-AKT and RAS-MAPK. Hence, it is anticipated that more cases with high PD-L1 expression had concomitant EGFR and KRAS mutations. Notably, only three patients in the present study had concomitant EGFR and KRAS mutations. We should interpret this result with caution. In addition, positive PD-L1 expression was marginally significantly associated with high CD8+ TIL density in this population, suggesting high PD-L1 expression of CD8+ TILs in EGFR-mutant NSCLC. Further investigation of the potential role of PD-1/PD-L1 pathway in inhibiting CD8+ TIL function in EGFR-mutant NSCLC is required.

    Figure 2 The flowchart of publication selection.

    We further evaluated the prognostic value of PD-L1 expression in surgically resected NSCLC with EGFR mutations. As expected, positive PD-L1 expression was significantly associated with inferior OS and CD8+ TIL density was marginally correlated with a longer OS. When we combined PD-L1 expression and CD8+ TIL density, the total populations could be divided into three groups with distinct prognoses. Similarly, a large number of studies consistently reported positive PD-L1 expression to be an independent negative prognostic factor in NSCLC. In 2014, Azuma et al.35assessed the prognostic value of PD-L1 expression in 164 surgically resected NSCLC, reporting high PD-L1 expression to be significantly associated with a shorter OS independently of other factors. Two recent meta-analyses also demonstrated the prognostic value of PD-L1 expression in NSCLC.However, another meta-analysis reported no statistically significant difference between PD-L1 expression and prognosis in patients with NSCLC38,39. Of note, the driver gene mutations of the populations in these studies were unknown. Thus, high-quality studies with larger sample sizes are needed to determine the prognostic value of PD-L1 expression in NSCLC with specific driver mutations. Our finding of the prognostic value of PD-L1 expression combined with CD8+ TIL density was consistent with those of other studies28. For example, Tokito et al.28observed that a combination of a lack of PD-L1 expression and CD8+ TIL density was significantly associated with favorable survival in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy, indicating that PD-L1 expression in combination with CD8+ TIL density was a useful predictive biomarker in patients with stage III NSCLC. These results suggested that the combination of PD-L1 expression and CD8+ TIL density may be useful to predict the prognosis and efficacy of immunotherapy in NSCLC.

    To clarify the predictive and prognostic value of PD-L1 expression in EGFR-mutant NSCLC patients treated with EGFR-TKIs, we conducted a meta-analysis of six eligible publications. Although preclinical studies reported that EGFR activation could induce PD-L1 expression to facilitate immune escape and that EGFR-TKI could significantly down-regulate PD-L1 expression in EGFR-mutant NSCLC cells18,35, the pooled results indicated that positive PD-L1 expression was not correlated with OS or PFS in this population. Whether PD-L1 expression is a reliable biomarker for EGFR-TKI treatment in advanced EGFR-mutant NSCLC patients requires further investigation.

    The current study had several limitations. First, the number of publications included in the meta-analysis was relatively small and all were retrospective studies. Second,publication bias is inevitable in this area of research. We identified several abstracts published at meetings withoutfurther detailed publications and excluded these abstracts from the meta-analysis. Third, the quality of data was heterogeneous due to a multitude of confounding factors(laboratory conditions, PD-L1 antibody, cutoff values of PD-L1 expression, etc.) that made direct comparisons difficult.

    Table 3 Baseline characteristics of included studies

    Figure 3 Meta-analysis to evaluate the predictive (A) and prognostic (B) value of high PD-L1 expression in EGFR-mutant NSCLC treated with EGFR-TKIs.

    In conclusion, the present study showed that PD-L1 expression had a particular clinicopathological feature and was correlated with a shorter OS in patients with EGFR-mutant NSCLC. The combination of PD-L1 expression and CD8+ TIL density more precisely differentiated subpopulations with distinct prognoses after surgery. Positive PD-L1 expression was neither the predictive nor the prognostic factor in EGFR-mutant NSCLC patients treated with EGFR-TKIs. These results suggested that a meaningful graded prognostic assessment for patients with surgical EGFR-mutant NSCLC should incorporate PD-L1 and CD8+TILs and that PD-L1 expression should not be evaluated as a biomarker of EGFR-TKIs.

    Acknowledgements

    This study was supported in part by grants from the National Natural Science Foundation of China (Grant No. 81672286,81772467 and 81874036), “Shuguang Program” supported by Shanghai Education Development Foundation and Shanghai Municipal Education Commission (Grant No. 16SG18), the Chronic Diseases Program of Shanghai Shen Kang Pharmaceutical Development Co. Ltd (Grant No. SHDC 12015314).

    Conflict of interest statement

    No potential conflicts of interest are disclosed.

    天天一区二区日本电影三级| 国产女主播在线喷水免费视频网站 | 亚州av有码| 国内揄拍国产精品人妻在线| 亚洲国产精品合色在线| 欧美丝袜亚洲另类 | 亚洲在线自拍视频| 亚洲欧美精品综合久久99| 亚洲四区av| 美女xxoo啪啪120秒动态图| 男女做爰动态图高潮gif福利片| 亚洲专区国产一区二区| 尾随美女入室| 中文在线观看免费www的网站| 国产亚洲欧美98| 免费搜索国产男女视频| 亚洲美女视频黄频| 特级一级黄色大片| 成人二区视频| 春色校园在线视频观看| 久久久久久大精品| av天堂在线播放| 18+在线观看网站| 真人做人爱边吃奶动态| 99在线视频只有这里精品首页| 嫩草影院新地址| 久久亚洲精品不卡| 成人av一区二区三区在线看| 欧美潮喷喷水| 国产日本99.免费观看| 69人妻影院| 亚洲18禁久久av| 亚洲专区中文字幕在线| 国产精品乱码一区二三区的特点| 亚洲天堂国产精品一区在线| 国内精品宾馆在线| 波多野结衣高清作品| 美女大奶头视频| 国产午夜福利久久久久久| 99精品在免费线老司机午夜| 麻豆成人午夜福利视频| 欧美黑人欧美精品刺激| 国产精品福利在线免费观看| 国产在线精品亚洲第一网站| 男女视频在线观看网站免费| 床上黄色一级片| 久久人人精品亚洲av| 精品午夜福利视频在线观看一区| 国产91精品成人一区二区三区| 我的老师免费观看完整版| 亚洲av中文字字幕乱码综合| 欧美3d第一页| 久久久久久国产a免费观看| 日本成人三级电影网站| 欧美3d第一页| 国内毛片毛片毛片毛片毛片| 日本色播在线视频| 成人特级黄色片久久久久久久| 黄色一级大片看看| 久久精品国产亚洲av涩爱 | 中文字幕精品亚洲无线码一区| 国产精品爽爽va在线观看网站| 男女啪啪激烈高潮av片| 两性午夜刺激爽爽歪歪视频在线观看| 国产亚洲精品av在线| 99久久精品一区二区三区| 亚洲第一电影网av| 久久九九热精品免费| 18禁裸乳无遮挡免费网站照片| 日本色播在线视频| 国产精品久久久久久亚洲av鲁大| 午夜福利高清视频| 亚洲一区二区三区色噜噜| 黄色一级大片看看| 不卡视频在线观看欧美| 成人综合一区亚洲| 国产成人a区在线观看| 欧美极品一区二区三区四区| 欧美极品一区二区三区四区| 免费看av在线观看网站| 成人av在线播放网站| 国产精品嫩草影院av在线观看 | 我要看日韩黄色一级片| 久久人人爽人人爽人人片va| 亚洲国产精品sss在线观看| 国产极品精品免费视频能看的| 中文字幕av在线有码专区| 男人狂女人下面高潮的视频| 亚洲av不卡在线观看| 亚洲午夜理论影院| 男女之事视频高清在线观看| 变态另类丝袜制服| 日日撸夜夜添| 国产精品国产三级国产av玫瑰| 久久久成人免费电影| 久久亚洲精品不卡| 亚洲熟妇中文字幕五十中出| 免费av毛片视频| 国产爱豆传媒在线观看| ponron亚洲| 1000部很黄的大片| 在线观看免费视频日本深夜| 亚洲精品一卡2卡三卡4卡5卡| 欧美最新免费一区二区三区| 成年版毛片免费区| 午夜视频国产福利| 亚洲av中文字字幕乱码综合| 国产精品不卡视频一区二区| 在线观看舔阴道视频| 亚洲性久久影院| 欧美绝顶高潮抽搐喷水| 日韩,欧美,国产一区二区三区 | 最新在线观看一区二区三区| 非洲黑人性xxxx精品又粗又长| 国产日本99.免费观看| 久久久国产成人精品二区| 精品无人区乱码1区二区| 日本撒尿小便嘘嘘汇集6| 中文字幕精品亚洲无线码一区| 国产精品一区www在线观看 | 欧美绝顶高潮抽搐喷水| 波野结衣二区三区在线| 国产乱人伦免费视频| 亚洲性久久影院| 国语自产精品视频在线第100页| 在线a可以看的网站| 成人特级黄色片久久久久久久| 日本黄大片高清| 1000部很黄的大片| 日韩欧美国产一区二区入口| 国产真实伦视频高清在线观看 | 国产亚洲精品久久久com| 亚洲人与动物交配视频| 成人二区视频| 亚洲人成网站在线播| 欧美国产日韩亚洲一区| 在线播放国产精品三级| 尤物成人国产欧美一区二区三区| 国产av一区在线观看免费| 99热这里只有是精品50| 国产 一区 欧美 日韩| 久久精品国产亚洲av天美| 色av中文字幕| 高清在线国产一区| 免费一级毛片在线播放高清视频| 国产精品人妻久久久久久| 国产aⅴ精品一区二区三区波| 国产亚洲欧美98| 婷婷丁香在线五月| 亚洲欧美精品综合久久99| 香蕉av资源在线| 久久精品人妻少妇| 国产精品福利在线免费观看| 久久亚洲精品不卡| 变态另类丝袜制服| 亚洲aⅴ乱码一区二区在线播放| 一边摸一边抽搐一进一小说| 日本爱情动作片www.在线观看 | 成人毛片a级毛片在线播放| 我的老师免费观看完整版| 婷婷精品国产亚洲av| 久久久午夜欧美精品| 精品福利观看| 日本-黄色视频高清免费观看| 久久热精品热| 日本与韩国留学比较| 精华霜和精华液先用哪个| avwww免费| 久久久久久久久大av| 国产亚洲91精品色在线| 国产黄a三级三级三级人| 我要看日韩黄色一级片| 一边摸一边抽搐一进一小说| 亚洲成人久久爱视频| 午夜激情福利司机影院| 特大巨黑吊av在线直播| 日本一本二区三区精品| 国产av麻豆久久久久久久| 黄色配什么色好看| 日本成人三级电影网站| 91午夜精品亚洲一区二区三区 | 乱系列少妇在线播放| 午夜激情欧美在线| 干丝袜人妻中文字幕| 精品久久久久久久久久久久久| 亚洲人成网站高清观看| 91狼人影院| 国产熟女欧美一区二区| 又粗又爽又猛毛片免费看| 国产精品国产三级国产av玫瑰| 亚洲av美国av| 舔av片在线| 亚洲最大成人手机在线| 欧美色欧美亚洲另类二区| 九九爱精品视频在线观看| 天堂影院成人在线观看| 免费人成在线观看视频色| 色综合色国产| 久久久午夜欧美精品| 一本久久中文字幕| 最近中文字幕高清免费大全6 | 国产精品久久电影中文字幕| 在线播放国产精品三级| 联通29元200g的流量卡| 搡老熟女国产l中国老女人| 小说图片视频综合网站| 亚洲专区中文字幕在线| 一a级毛片在线观看| 久久人人爽人人爽人人片va| 日本爱情动作片www.在线观看 | 久久久久久大精品| 亚洲精品久久国产高清桃花| 好男人在线观看高清免费视频| 国模一区二区三区四区视频| aaaaa片日本免费| 男人狂女人下面高潮的视频| 亚洲av成人精品一区久久| 在线播放无遮挡| 午夜福利在线观看免费完整高清在 | 大型黄色视频在线免费观看| 自拍偷自拍亚洲精品老妇| 久久婷婷人人爽人人干人人爱| 五月玫瑰六月丁香| 亚洲性夜色夜夜综合| 成人午夜高清在线视频| 亚洲av免费高清在线观看| 成人鲁丝片一二三区免费| 国产精品电影一区二区三区| 欧美日韩瑟瑟在线播放| 在线天堂最新版资源| 91午夜精品亚洲一区二区三区 | 18禁黄网站禁片午夜丰满| 91精品国产九色| 成熟少妇高潮喷水视频| 国产在视频线在精品| 国产探花在线观看一区二区| 亚洲经典国产精华液单| 午夜福利在线在线| 深夜a级毛片| 久久久成人免费电影| 极品教师在线免费播放| 午夜精品在线福利| 国产69精品久久久久777片| 又黄又爽又刺激的免费视频.| 中文字幕高清在线视频| 欧美日本视频| 日韩中文字幕欧美一区二区| 亚洲国产精品sss在线观看| 久久久久久国产a免费观看| 成人无遮挡网站| 欧美极品一区二区三区四区| 成人一区二区视频在线观看| 三级男女做爰猛烈吃奶摸视频| 五月伊人婷婷丁香| 深夜精品福利| 亚洲七黄色美女视频| 18禁黄网站禁片午夜丰满| 亚洲三级黄色毛片| 亚洲精品一卡2卡三卡4卡5卡| 美女免费视频网站| av在线天堂中文字幕| 嫁个100分男人电影在线观看| 一级av片app| 赤兔流量卡办理| 日本黄大片高清| 十八禁网站免费在线| 最后的刺客免费高清国语| 如何舔出高潮| 亚洲成av人片在线播放无| 一级黄色大片毛片| 日韩中字成人| 亚洲自偷自拍三级| 欧美成人a在线观看| 国产精品伦人一区二区| 真人一进一出gif抽搐免费| 九九爱精品视频在线观看| 午夜福利成人在线免费观看| 婷婷色综合大香蕉| 久久香蕉精品热| 搡老熟女国产l中国老女人| 免费搜索国产男女视频| 天堂√8在线中文| 亚洲七黄色美女视频| 国产精品美女特级片免费视频播放器| 欧美国产日韩亚洲一区| 国产欧美日韩精品一区二区| 在线观看66精品国产| 亚洲精品亚洲一区二区| 国产精品,欧美在线| 亚洲av第一区精品v没综合| bbb黄色大片| 中文字幕久久专区| 动漫黄色视频在线观看| 国产av不卡久久| 无遮挡黄片免费观看| 亚洲国产欧洲综合997久久,| 午夜福利在线观看吧| 色视频www国产| 国产av麻豆久久久久久久| 亚洲精品一卡2卡三卡4卡5卡| 精品久久久久久久久亚洲 | 国产精品美女特级片免费视频播放器| 欧美xxxx性猛交bbbb| 精品一区二区三区av网在线观看| 欧美三级亚洲精品| 亚洲欧美日韩无卡精品| 国产精品三级大全| 久久午夜亚洲精品久久| 国产高清三级在线| 国产精品久久久久久久电影| 久久婷婷人人爽人人干人人爱| 成人午夜高清在线视频| 成人鲁丝片一二三区免费| 91在线观看av| 国产爱豆传媒在线观看| 国产精品一区二区三区四区久久| 一本久久中文字幕| 国产精品一区二区免费欧美| 国内精品美女久久久久久| 美女黄网站色视频| 久久国内精品自在自线图片| 在线播放国产精品三级| 欧美激情久久久久久爽电影| 免费看a级黄色片| 91久久精品国产一区二区三区| 午夜福利在线观看吧| 免费黄网站久久成人精品| 又黄又爽又免费观看的视频| 自拍偷自拍亚洲精品老妇| 噜噜噜噜噜久久久久久91| 国产精品嫩草影院av在线观看 | 在线观看舔阴道视频| 99久久久亚洲精品蜜臀av| 波多野结衣高清作品| 麻豆成人午夜福利视频| 天堂网av新在线| 午夜福利在线观看免费完整高清在 | 精品国产三级普通话版| 两个人视频免费观看高清| 亚洲精品456在线播放app | 九色成人免费人妻av| 国产精品久久视频播放| 亚洲第一电影网av| 亚洲色图av天堂| 国内揄拍国产精品人妻在线| 亚洲国产精品成人综合色| 亚洲精品456在线播放app | 变态另类丝袜制服| 精品一区二区三区视频在线| 淫妇啪啪啪对白视频| 全区人妻精品视频| 国产免费av片在线观看野外av| 啪啪无遮挡十八禁网站| 精品午夜福利视频在线观看一区| 欧美绝顶高潮抽搐喷水| 国产一区二区在线观看日韩| 亚洲欧美日韩卡通动漫| 女的被弄到高潮叫床怎么办 | 一级毛片久久久久久久久女| 韩国av在线不卡| 欧美激情国产日韩精品一区| 婷婷精品国产亚洲av在线| 日韩欧美免费精品| 精品日产1卡2卡| 免费无遮挡裸体视频| 国产精品一及| 午夜福利视频1000在线观看| 国产成人a区在线观看| 欧美区成人在线视频| 国产精品国产三级国产av玫瑰| 午夜免费激情av| 国产大屁股一区二区在线视频| 我的老师免费观看完整版| 亚洲av免费在线观看| 国产精品美女特级片免费视频播放器| 看黄色毛片网站| 2021天堂中文幕一二区在线观| 观看美女的网站| 亚洲图色成人| 在线天堂最新版资源| 88av欧美| 成年免费大片在线观看| 国产亚洲精品综合一区在线观看| 国产 一区精品| 色精品久久人妻99蜜桃| 一卡2卡三卡四卡精品乱码亚洲| 久久久久久久久中文| 夜夜看夜夜爽夜夜摸| 亚洲18禁久久av| 中文字幕精品亚洲无线码一区| 亚洲性久久影院| 午夜a级毛片| 中亚洲国语对白在线视频| 亚洲avbb在线观看| 国产精品久久久久久久电影| 国产一区二区亚洲精品在线观看| 免费看av在线观看网站| 熟女电影av网| 色哟哟·www| 精品日产1卡2卡| 日本黄色视频三级网站网址| 国产蜜桃级精品一区二区三区| 国产人妻一区二区三区在| 久久精品国产亚洲av涩爱 | 别揉我奶头~嗯~啊~动态视频| 啦啦啦韩国在线观看视频| 91午夜精品亚洲一区二区三区 | 亚洲国产日韩欧美精品在线观看| 久久婷婷人人爽人人干人人爱| 麻豆国产av国片精品| 国产精品1区2区在线观看.| 哪里可以看免费的av片| 一进一出抽搐动态| 欧美极品一区二区三区四区| 国内精品久久久久精免费| 亚洲精品一区av在线观看| 免费电影在线观看免费观看| 午夜精品久久久久久毛片777| 日韩国内少妇激情av| 五月玫瑰六月丁香| 最新在线观看一区二区三区| 三级男女做爰猛烈吃奶摸视频| 婷婷六月久久综合丁香| 麻豆国产av国片精品| 国产成人一区二区在线| av国产免费在线观看| 狂野欧美激情性xxxx在线观看| 极品教师在线免费播放| aaaaa片日本免费| 麻豆成人av在线观看| 变态另类丝袜制服| 啦啦啦啦在线视频资源| 婷婷精品国产亚洲av| 有码 亚洲区| 亚洲av不卡在线观看| 国产免费一级a男人的天堂| 中文字幕熟女人妻在线| 亚洲男人的天堂狠狠| 成人毛片a级毛片在线播放| 搡老妇女老女人老熟妇| 免费黄网站久久成人精品| 在线观看av片永久免费下载| 亚洲精华国产精华精| 波多野结衣巨乳人妻| 国产一级毛片七仙女欲春2| 国产伦人伦偷精品视频| 精品99又大又爽又粗少妇毛片 | 亚洲av日韩精品久久久久久密| 欧美另类亚洲清纯唯美| 男女之事视频高清在线观看| 在线观看免费视频日本深夜| 琪琪午夜伦伦电影理论片6080| 蜜桃亚洲精品一区二区三区| 免费观看在线日韩| 久久久久久国产a免费观看| 九九爱精品视频在线观看| 91午夜精品亚洲一区二区三区 | 中文资源天堂在线| 日韩欧美一区二区三区在线观看| 国产人妻一区二区三区在| 成人高潮视频无遮挡免费网站| 色哟哟·www| 又爽又黄a免费视频| 国产精品福利在线免费观看| 日本欧美国产在线视频| 亚洲va日本ⅴa欧美va伊人久久| 日韩强制内射视频| 男女那种视频在线观看| 亚洲成人精品中文字幕电影| 亚洲四区av| 国产毛片a区久久久久| 国产精品自产拍在线观看55亚洲| 国产大屁股一区二区在线视频| av国产免费在线观看| 99热这里只有是精品在线观看| 亚洲国产高清在线一区二区三| 日本免费a在线| 又黄又爽又刺激的免费视频.| 美女大奶头视频| 成人av在线播放网站| 欧美激情国产日韩精品一区| 久久人人爽人人爽人人片va| 一卡2卡三卡四卡精品乱码亚洲| 人人妻,人人澡人人爽秒播| 一边摸一边抽搐一进一小说| 伦精品一区二区三区| 国产一区二区激情短视频| 欧美中文日本在线观看视频| 三级国产精品欧美在线观看| 亚洲av熟女| 亚洲午夜理论影院| 国产欧美日韩精品亚洲av| 国产精品久久电影中文字幕| 国产精品一区二区性色av| 久久九九热精品免费| 亚洲无线观看免费| 97超视频在线观看视频| 九九爱精品视频在线观看| 欧美又色又爽又黄视频| 18禁在线播放成人免费| 人妻丰满熟妇av一区二区三区| 亚洲综合色惰| 老司机午夜福利在线观看视频| 中文字幕av成人在线电影| 欧美成人性av电影在线观看| 中国美白少妇内射xxxbb| 九色成人免费人妻av| 老师上课跳d突然被开到最大视频| 亚洲国产精品sss在线观看| 中文字幕精品亚洲无线码一区| 成年女人看的毛片在线观看| 久久亚洲真实| 国产精品一区二区三区四区免费观看 | 婷婷精品国产亚洲av| 国产一区二区三区在线臀色熟女| 国产在线精品亚洲第一网站| 国产精品,欧美在线| 欧洲精品卡2卡3卡4卡5卡区| 日韩中字成人| 精品无人区乱码1区二区| 大型黄色视频在线免费观看| 午夜福利视频1000在线观看| 国产高清不卡午夜福利| 99久久无色码亚洲精品果冻| 91狼人影院| 99九九线精品视频在线观看视频| 99久久成人亚洲精品观看| 色噜噜av男人的天堂激情| 99热6这里只有精品| 三级国产精品欧美在线观看| 性色avwww在线观看| 免费av不卡在线播放| 欧美zozozo另类| 欧美绝顶高潮抽搐喷水| 91久久精品国产一区二区三区| 亚洲人成网站高清观看| 久久精品夜夜夜夜夜久久蜜豆| 蜜桃久久精品国产亚洲av| 成人高潮视频无遮挡免费网站| 变态另类丝袜制服| 成人美女网站在线观看视频| 国产精品,欧美在线| 中文在线观看免费www的网站| 亚洲av免费在线观看| 老师上课跳d突然被开到最大视频| 日韩欧美三级三区| 国内精品久久久久精免费| 长腿黑丝高跟| 色av中文字幕| 久久精品久久久久久噜噜老黄 | 久久精品国产亚洲av天美| 少妇丰满av| 亚洲图色成人| 草草在线视频免费看| 久久久久精品国产欧美久久久| 久久婷婷人人爽人人干人人爱| 成人亚洲精品av一区二区| 少妇人妻一区二区三区视频| 麻豆av噜噜一区二区三区| 2021天堂中文幕一二区在线观| 日本撒尿小便嘘嘘汇集6| 色在线成人网| 亚洲av不卡在线观看| 久久精品夜夜夜夜夜久久蜜豆| 一本精品99久久精品77| 丰满的人妻完整版| 欧美一级a爱片免费观看看| 亚洲国产欧洲综合997久久,| 麻豆一二三区av精品| 日本爱情动作片www.在线观看 | 老熟妇仑乱视频hdxx| 少妇人妻精品综合一区二区 | 欧美成人性av电影在线观看| 亚洲欧美日韩东京热| 亚洲aⅴ乱码一区二区在线播放| 人妻制服诱惑在线中文字幕| 少妇猛男粗大的猛烈进出视频 | 日韩欧美三级三区| 黄色欧美视频在线观看| 国产国拍精品亚洲av在线观看| 看片在线看免费视频| 亚洲最大成人av| 精品久久久久久久人妻蜜臀av| 亚洲无线在线观看| 亚洲中文日韩欧美视频| 男女之事视频高清在线观看| 看免费成人av毛片| 男女之事视频高清在线观看| h日本视频在线播放| 高清毛片免费观看视频网站| 三级国产精品欧美在线观看| 国产成人aa在线观看| 神马国产精品三级电影在线观看| 非洲黑人性xxxx精品又粗又长| 欧美日本亚洲视频在线播放| 欧美另类亚洲清纯唯美| 国产精品,欧美在线| 免费人成在线观看视频色| 丰满乱子伦码专区| 特级一级黄色大片| 免费搜索国产男女视频| 日本成人三级电影网站| 麻豆国产av国片精品| 波多野结衣高清无吗| 精品无人区乱码1区二区| 亚洲成人精品中文字幕电影| 欧美成人免费av一区二区三区| 欧美日韩精品成人综合77777| 色尼玛亚洲综合影院| 亚洲18禁久久av| 人人妻人人看人人澡| 偷拍熟女少妇极品色| 伦理电影大哥的女人| 免费观看的影片在线观看| 又粗又爽又猛毛片免费看|